Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
testing recent lows...
watching and will BUY more if we get to my TARGET BUY range.
likely we put in a double-bottom soon from which to rally at year-end and well into early 2018!
ajimhothough
safe genes
https://www.darpa.mil/program/safe-genes
darpa instituting technology safeguards...a good thing for the emerging industry and the world.
Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints in the United States. The company has market cap of $10.01 million. The companyÂ’s gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It currently has negative earnings. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints.
fibrocell & intrexon gene therapy venture
https://kgazette.com/fibrocell-science-inc-fcsc-reaches-0-68-52-week-low-fil-ltd-has-raised-its-cboe-hldgs-cboe-position/
ZIOPHARM reportrs clinical data from Data from T-Cell Therapy Programs; shows continued survival benefit
5:25 AM ET 12/11/17 | Briefing.com
Co announced data supporting its non-viral approach to rapid manufacture of chimeric antigen receptor (CAR)-modified T cells to treat patients with cancers Two trials demonstrated that first-generation SB-modified CD19-specific CAR+ T cells appear to provide long-term cancer control when infused after hematopoietic stem-cell transplantation (HSCT) for patients with advanced CD19+ malignancies and could be detected years after administration in some recipients. All seven patients with advanced CD19+ non-Hodgkin's lymphoma (NHL) that received autologous T cells were alive at a median survival of 40 months since infusion, with progression-free survival (PFS) reported at 86% and overall survival (OS) at 100%. For 19 patients with advanced CD19+ acute lymphoblastic leukemia (ALL) and NHL infused with allogeneic T cells following HSCT, nine patients were alive with a median survival of 31 months. The PFS rate and OS rates are 32% and 49%, respectively. Of the subset of eight patients who received donor-derived T cells after haploidentical HSCT, PFS and OS rates are 50% and 63%, respectively. Persistence of circulating SB-modified CAR+ T cells was demonstrated at two years in an autologous and allogeneic patient and for four years in two autologous patients.
ZIOPHARM is advancing its non-viral Sleeping Beauty (SB) platform towards point-of-care (P-O-C) for very rapid manufacturing of genetically modified CAR+ T cells. Data presented from first- and second-generation SB clinical trials demonstrate safety, tolerability, disease response, long-term survival, and persistence of infused CD19-specific CAR+ T cells. Preclinical studies showed that P-O-C CAR+ T cells co-expressing membrane-bound interleukin-15 (mbIL15) and a control switch manufactured within two days do not require activation or propagation in tissue culture to achieve anti-tumor effects and prolonged T-cell survival. Building on these data, the Company plans to initiate its first P-O-C clinical trial in 2018.
zeopharm/intrexon t-cell update
http://ir.ziopharm.com/releasedetail.cfm?ReleaseID=1051299
carry on!!! ;)
bioengineered mosquitos approved by epa to combat zika, dengue..!!!
https://seekingalpha.com/news/3310720-epa-oks-release-bioengineered-mosquitoes-20-u-s-states
EPA OKs release of bioengineered mosquitoes in 20 U.S. states
Nov. 9, 2017 3:57 PM ET|By: Douglas W. House, SA News Editor
On November 3, the Environmental Protection Agency (EPA) approved the release of bioengineered mosquitoes in 20 states and the District of Columbia beginning next summer as a tactic to reduce the risk of mosquito-borne diseases like Zika and Dengue.
The Asian Tiger mosquitoes, bred by Lexington, KY-based startup MosquitoMate, contain the bacterium Wolbachia pipientis which interferes with reproduction by preventing paternal chromosomes from fully forming.
Much of the mosquito-infested Southeast is excluded since MosquitoMate has not performed field trials there.
Intrexon's (XON +1.2%) Oxitec is pursuing a similar track with its Friendly Aedes mosquito (OX513A) which are genetically engineered to inherit a gene that causes death before reaching reproductive age.
Verily Life Sciences recently launched a field study in Fresno, CA on its sterile mosquitoes, also Aedes aegypti.
1st sale in June 2017
https://aquabounty.gcs-web.com/node/8326/html
crispr proposed efficiency rules
https://phys.org/news/2017-12-scientists-efficiency-gene-technology.html
all good for the emerging gene editing industry!
fyi...The Washington Post picked up the story as well.
$56B Synthetic Rubber Market in 2020
https://en.wikipedia.org/wiki/Synthetic_rubber
XON just announced that the company is building a plant which will be competed within 18 months to participate and maybe to lead on cost!
Norway's Common-Sense Model for Aquaculture
https://thefishsite.com/articles/norwegian-legislative-debate-offers-hope-for-gene-editing-in-aquaculture
FDA APPROVAL, MARKET APPROVAL NEXT?!?!
https://geneticliteracyproject.org/2017/12/05/anti-biotech-environmental-groups-trying-kill-roll-aquabountys-sustainable-salmon/?mc_cid=c20bae519c&mc_eid=b2383a0fbd
As mentioned in the attached article, this so-called" battle is nothing more than economics, market-share protection and clearly NOT safety-related. THE FDA has "ALREADY' APPROVED the elegantly optimized design and it's selling quite well now. I think that aquabounty will first sell quite effectively and profitably, as mentioned, in select, niche, receptive markets then will expand over time with proven-track records, benefits and efficacy. ajimhothough
https://www.wired.com/story/what-is-crispr-gene-editing
source: WIRED - what is crispr gene editing
excellent WIRED article and video explaining the definitive gene editing tool crispr.
from the video, imagine if one had a disease that could be elegantly cured by gene editing, wouldn't you jump at the chance to stave off the profession of the disease? I believe that I would. now think about genetically optimizing other things in nature that are prudently, safely feasible to optimize, that is what i believe is intrexon's mission, in a nutshell. ajimhothough
11/30/2017 xon ceo insider buys!!!
http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11923250&type=HTML&symbol=XON&companyName=Intrexon+Corporation&formType=4&dateFiled=2017-12-04
captain kirk ROCKS!]
xon's "precigen" subsidiary collaborations
with ziopharm!
ziopharm & intrexon pipeline
http://ziopharm.com/pipeline/dna-therapeutics
FDA APPROVAL!
AquaBounty/AquaAdvantage Salmon
I'll have my 8 oz. salmon broiled with herbs & lemon, wild rice and asparagus sides and a sancerre white wine from france.
http://aquabounty.com
AquaBounty Symbol: AQB is a biotech co. focused on enhancing productivity in the aquaculture market and a majority-owned sub of intrexon....trout & tilapia next.
In Nov. 2015 AQB was granted FDS approval for the production, sale and consumption of its AquaAdvantage Salmon - a game-changer that will bring healthy and nutritious food to consumers in an environmentally responsible manner without damaging the ocean and other marine habitats.
The AquaAdvantage fish program is elegantly based on XON's single, molecular modification in fish that results in more rapid growth in early development.
It could happen but this has been so volatile I don't think it would last
14.50 by friday LOL
I thought XON was suppose to be the stock of this decade not the next one.
Synthetic Biology Market Worth $26B by 2025
https://www.medgadget.com/2017/11/synthetic-biology-market-worth-us-26-billion-by-2025-due-to-increasing-demand-for-enhanced-vaccines-and-drugs.html
Book Recommendation on Gene Editing
A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution Kindle Edition
by Jennifer A. Doudna (Author),? Samuel H. Sternberg (Author)
Patents Assigned to Intrexon Corporation
https://patents.justia.com/assignee/intrexon-corporation
GDO, GEO, GOO or GOD
GENETICALLY DESIGNED ORGANISM
GENETICALLY ENHANCED ORGANISM
GENETICALLY OPTIMIZED ORGANISM or
GENETICALLY OPTIMIZED DESIGN....GOD ! ! !
GMO, GENETICALLY MODIFIED ORGANISM...NOT SO MUCH...
LET'S CHANGE THE PERCEPTION OF GENE DESIGN, ENHANCEMENT, OPTIMIZATION...the capability to do so is from...GOD...aimho
Represents intrexon's pre-cut, sliced arctic apples in small bags only...this will be big!!!
Large Market Opportunity in Fruits & Vegetables
Arctic® fresh sliced apples represent Intrexon’s initial non-browning product launch into the commercial marketplace:
Projected outlook for Arctic® fresh apple slices
2020
$20 million sales
2022
$100 million sales >50% GMs
2026
$500 million sales >50% GMs $200 million EBITDA
Non-browning fruits & vegetables under development at Intrexon:
Avocados Pears CherriesLettuce
Alright, bottom is in. Let's rock. $15
Not today. Maybe Friday?
Not today. Maybe Friday
arctic golden apples
commercial launch in q4 2017 !
https://www.arcticapples.com/arctic-apples-r/arctic-golden/
btw..osf is a sub of xon.
RJ KIRK
I really believe that RJ, Captain Kirk needs to do a roadshow on his company since I believe that XON is not well understood by investors & analyst's for that matter...Barron's Biotechnology Roundtable would be an excellent venue. Beam Me Up Scottie! ;) GL
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing innovative gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.
ziopharm positive results using xon's trademarked technology !
https://ih.advfn.com/p.php?pid=nmona&article=76130296
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company developing new gene and cell-based immunotherapies for cancer, today announced positive data updates supporting survival benefit and the underlying immune system mechanism for Ad-RTS-hIL-12 plus veledimex, the Company’s controlled human interleukin-12 (hIL-12) gene therapy candidate for brain cancer, at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO). This gene therapy has demonstrated a targeted, anti-tumor immune response for the treatment of recurrent glioblastoma (rGBM).
New data presented shows median overall survival (mOS) of 12.5 months has been sustained for patients treated with Ad-RTS-hIL-12 plus 20mg of veledimex (n=15) at a longer mean follow-up time of 11.1 months as of October 18, 2017. This mOS of 12.5 months continues to compare favorably to the 5 to 8 months survival established in historical controls for patients with rGBM. Furthermore, the four patients with rGBM who received low-dose steroids maintained 100 percent survival at a mean follow-up time of 11.1 months. An anti-tumor effect was also evident with centralized review of magnetic resonance imaging (MRI) showing decreasing size of brain tumor lesions in several patients.
Additionally, data linking the intra-tumor production of hIL-12 to patients’ overall survival was presented by Francois Lebel, M.D., Chief Medical Officer of ZIOPHARM during an oral poster session, “A Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex in Adult Recurrent Glioblastoma.” Highlights of this presentation include:
Immunohistochemistry analyses from three of three patient biopsies after completion of veledimex demonstrated that IL-12 activates and sustains an immune response within rGBM;
All three biopsies of rGBM lesions demonstrated evidence of an anti-tumor response with extensive infiltration of CD8+ T cells within the rGBM;
Biopsies all showed sustained (greater than 4 months) production of interferon-gamma, a cytokine crucial to arming an immune response in the tumor microenvironment;
Ratio of circulating killer CD8+ T cells to suppressor FOXP3+ T cells correlates with survival;
Interferon-gamma was undetectable in the blood at the time of biopsies providing further evidence of an on-target response;
Expression levels of both PD-1 and PD-L1 were upregulated in all the biopsies, which suggests added potential efficacy for combining Ad-RTS-hIL-12 plus veledimex with an immune checkpoint inhibitor;
Ad-RTS-hIL-12 plus veledimex continues to be safe and well tolerated, as adverse events (AE) were predictable and reversible, neurologic AEs were relatively mild and transient, and there were no drug-related deaths.
“These new mechanistic data, especially taken together with the promising extension of patients’ median overall survival, provide additional validation that controlling IL-12 can engage the body’s own immune system safely to generate a T-cell response against rGBM. We are excited to see increasing evidence of a targeted, local immune response making brain tumors hot and illustrating how this immunotherapy contributes to patients’ survival,” said Dr. Antonio Chiocca, M.D., Ph.D., lead author of this presentation and the 2017 President of the Society for Neuro-Oncology, Professor of Neurosurgery at Harvard Medical School, Surgical Director of the Center for Neuro-oncology at Dana-Farber Cancer Institute, and Chairman of Neurosurgery and Co-Director of the Institute for the Neurosciences at Brigham and Women's Hospital.
Additional SNO presentations included:
“A Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex in Pediatric Brain Tumors,” was presented in a poster by Stewart Goldman, M.D., Division Head Hematology-Oncology, Neuro-Oncology & Stem Cell Transplantation at Ann & Robert H. Lurie Children's Hospital in Chicago. The Company previously announced that the first patient was dosed in this open-label study designed to assess the safety and tolerability of a single intratumoral injection of Ad-RTS-hIL-12 plus veledimex in children.
“Controlled Expression of IL-12 Improves Survival in Glioma by Activating the Immune Response in Mice and Humans,” was presented during an oral session by John A. Barrett, Ph.D., Vice President of R&D/Translational Medicine at ZIOPHARM.
Dr. Barrett delivered a second oral presentation, “Controlled Expression of IL-12 Improves Survival in Glioma by Activating the Immune Response in Mice and Humans.”
A copy of all four SNO presentations is available in the Presentations and Publications section of the Company's website, www.ziopharm.com.
“The established safety profile and tolerability of intra-tumor administration of Ad-RTS-hIL-12 plus oral veledimex, the durability of the overall survival results, and now the powerful evidence of sustained immune activation all support our goal of delivering a new treatment option to patients with recurrent glioblastoma,” said Dr. Lebel. “We continue to work with regulators and thought leaders to initiate a pivotal study of Ad-RTS-hIL-12 plus veledimex in this setting before year end. In addition, the immunohistochemistry analyses revealing extensive and persistent immune cell infiltration within brain tumors and upregulation of immune checkpoint biomarkers support our initiation of a study of Ad-RTS-hIL-12 plus veledimex combined with an anti-PD-1 drug this year.”
Conference Call and Webcast
In connection with this announcement, ZIOPHARM will host a conference call and webcast slide presentation featuring Drs. Chiocca and Goldman today, Nov. 20, at 10:15 a.m. ET. The call can be accessed by dialing 1-844-309-0618 (U.S. and Canada) or 1-661-378-9465 (international). The conference ID number is 8089664. To access the accompanying slides and live webcast, or the subsequent archived recording, visit the "Investors & Media" section of the ZIOPHARM website at www.ziopharm.com. The webcast will be recorded and available for replay on the Company's website for two weeks.
About Ad-RTS-hIL-12 plus Veledimex:
ZIOPHARM is advancing Ad-RTS-hIL-12 plus veledimex as a gene therapy for glioblastoma. Ad-RTS-hIL-12 is an adenoviral vector administered via a single injection into the tumor and engineered to express hIL-12, a powerful cytokine that has demonstrated the potential to stimulate a targeted, anti-tumor immune response. The expression of hIL-12 is controlled and modulated with the RheoSwitch Therapeutic System® (RTS®) by the small molecule veledimex, an activator ligand which has been shown to cross the blood-brain barrier. The Company completed enrollment in a multi-center, Phase 1 dose escalation trial designed to evaluate Ad-RTS-hIL-12 in patients with recurrent or progressive Grade III or IV glioma. The trial evaluated three veledimex dosing cohorts (20mg, n = 15; 30mg, n = 4; and 40mg, n = 6). Patients undergoing resection were injected intratumorally with Ad 2 x 1011 viral particles and received daily oral activator veledimex for 15 doses. The majority of patients in the 20mg cohort had 2 or more recurrences prior to entry in the study, indicating very advanced disease. ZIOPHARM anticipates initiation of a pivotal registration trial for Ad-RTS-hIL-12 plus veledimex for the treatment of rGBM by the end of 2017. The Company has also initiated a Phase 1 study to evaluate the stereotactic administration of Ad-RTS-hIL-12 plus veledimex in adult patients with rGBM, as well as a trial to evaluate the gene therapy as a treatment for pediatric brain tumors. In addition, ZIOPHARM plans to initiate enrollment of adult patients with rGBM who will receive a single dose of Ad-RTS-hIL-12 plus veledimex in combination with a checkpoint inhibitor targeting programmed cell death protein 1 (PD-1) by the end of 2017.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing innovative gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.
Forward-Looking Safe-Harbor Statement:
This press release contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the progress and timing of the development of the Company's research and development programs. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These risks and uncertainties include, but are not limited to: the Company's ability to finance its operations and business initiatives and obtain funding for such activities; whether chimeric antigen receptor T cell (CAR-T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, or any of other product candidates will advance further in the preclinical research or clinical trial process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether chimeric antigen receptor T cell (CAR-T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, and the Company's other therapeutic products it develops will be successfully marketed if approved; the strength and enforceability of the Company's intellectual property rights; competition from other pharmaceutical and biotechnology companies; as well as other risk factors contained in the Company's periodic and interim reports filed from time to time with the Securities and Exchange Commission, including but not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 and subsequent reports that the Company may file with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and the Company does not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.
Trademarks
RheoSwitch Therapeutic System® and RTS® are registered trademarks of Intrexon Corporation.
It looks like I bought a piece of trash at $ 13,50 last Thursday.
I
It looks like a bought a piece of trash on Thursday @ 13.50.
xon insider buy
https://ih.advfn.com/p.php?pid=nmona&article=76105397
I am out. Best wishes to all.
Will listen in on the presentation tomorrow.
averaged-in 1000 shares @ 10.99
hope to hold xon as a core position for a long time since getting in well below the $16 ipo.
Followers
|
49
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
411
|
Created
|
08/24/13
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |